Keros Therapeutics is a biotechnology company that develops therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta. It offers KER-050, an engineered ligand trap comprised of a modified ligand-binding domain; KER-012, which is designed to bind to and inhibit the signaling of ligands that stimulate the proliferation of vascular endothelial and smooth muscle cells and fibroblasts; and KER-065, that binds to and inhibits TGF-ß ligands, including myostatin (GDF8) and activin A.